FDA approves Dexycu to treat cataract surgery inflammation

Icon Bioscience reported the FDA approved its new drug application for Dexycu, a dropless therapeutic designed to treat inflammation associated with cataract surgery.
The current standard treatment after cataract surgery is self-administered medicated eye drops, several times a day over several weeks. The Dexycu (dexamethasone intraocular suspension) treatment is applied as a single injection at the end of surgery, David S. Tierney, MD, president and CEO of Icon Bioscience, said in a press release.
The treatment uses Icon’s Verisome drug delivery technology to dispense a biodegradable

Full Story →